ClinicalTrials.gg
CompletedNCT03335566Updated Oct 31, 2018Results posted

An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

A Phase 3 interventional study of Sonazoid™ and SonoVue® in Liver Lesions, sponsored by GE Healthcare. Completed at 18 sites in 3 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-10-31.

Sponsored by GE Healthcare · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled May 2014, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
424
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of lesion diagnosis including diagnosis as benign versus malignant, specific lesion diagnosis, confidence in diagnosis, and quality of delineation of lesion-related blood vessels (from images obtained during vascular imaging) and detection of lesion presence and quality of delineation of the whole liver (from images obtained during whole liver imaging).

02

Conditions studied

  • Liver Lesions
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria:

  • Participant has at least 1 untreated focal liver lesions (FLL) but =\<8 lesions (excluding cysts) \<10 centimeter (cm) in diameter confirmed in a diagnostic examination performed in the past month (or past 3 months if lesion is benign) that can be visualised by non- contrast-enhanced (CE) ultrasound
  • Participant has had a dynamic CE-computed tomography (CE-CT) or CE-magnetic resonance imaging (CE-MRI) examination within the past month or is scheduled to have one in the month following inclusion in the study and the original images (or copies thereof) are/will be available. (This inclusion criterion does not apply for participants enrolled as training cases. Investigators will be asked to submit standard of truth/ reference diagnosis for training cases whenever possible, since the cases may be used for training and testing the blinded readers prior to the blinded read)
  • Participant is a 20- to 80-year-old inpatient or outpatient referred for an ultrasound examination of the liver
  • Participant is able and willing to comply with study procedures and will give their signed and dated
  • The participant, if female, is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), (cessation of menses for more than 1 year), or non-lactating, or if of the results of a serum or urine human chorionic gonadotropin pregnancy test, performed on the day of medicinal product (IMP) administration (with the result known before IMP administration), are negative

Exclusion Criteria:

  • The participant has an acute clinically fatal condition (i.e., not expected to survive for at least 6 months)
  • The participant has previously received Sonazoid™ or has received SonoVue® within the past 30 days
  • The participant has undergone or is undergoing systemic or loco-regional chemotherapy, or radiation therapy
  • The participant is participating in another clinical trial with an unregistered medicinal product, or less than 30 days have passed since completing participation in such a trial
  • The participant has a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension or shock)
  • The participant has known to sulphur hexafluoride or to any of the components of SonoVue®
  • The participant has undergone or plans to undergo liver or surgery within the 24 hours before or after this examination
  • The participant has undergone or plans to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, magnetic resonance imaging (MRI) contrast agent or another ultrasound contrast agent) within the 24 hours before or after this examination
  • The participant is considered to be unsuitable to participate in the study by the investigator
  • The participant is known to have a right-to-left shunt, severe pulmonary hypertension (pulmonary artery pressure >90 millimeter of mercury (mmHg) or uncontrolled systemic hypertension
  • The participant has a recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within the last 7 days, significant worsening of cardiac symptoms within the last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of [ECG], laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders
  • The participant has adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
  • The participant has known thrombosis within the liver, portal, or mesenteric veins
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
424 participants (actual)

Study arms

  • Experimental
    Sonazoid™

    Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.

    Drug: Sonazoid™

  • Active comparator
    SonoVue®

    Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).

    Drug: SonoVue®

Interventions

  • Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.

  • Single Dose of SonoVue® 2.4 mL as I.V. injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth

    Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast \& post-contrast images were recorded, \& for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.

    Time frame: Pre-administration up to 15 minutes post-administration

Secondary outcomes

  1. Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)

    For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.

    Time frame: Pre-administration up to 15 minutes post-administration

  2. Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results

    Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).

    Time frame: Pre-administration up to 15 minutes post-administration

  3. Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth

    The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.

    Time frame: Pre-administration up to 15 minutes post-administration

07

Results

Posted Aug 27, 2018

Participant flow

The study was conducted at 17 centres in China, Korea and Taiwan. A total of 424 participants were enrolled between 11 May 2014 and 9 April 2015.

Participant flow — Overall Study
MilestoneSonazoid™SonoVue®
Started218206
Completed214203
Not completed43
Withdrew: Adverse event01
Withdrew: Lost to follow-up10
Withdrew: Technical problems10
Withdrew: Protocol violation10
Withdrew: Other than specified above12

Outcome measures

PrimaryPercentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth

Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast \& post-contrast images were recorded, \& for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.

Time frame:
Pre-administration up to 15 minutes post-administration
Reported as:
Number · percentage of participants
Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth
percentage of participantsSonazoid™SonoVue®
Reader 118.124.2
Reader 222.114.6
Reader 317.016.7
SecondaryNumber of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)

For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.

Time frame:
Pre-administration up to 15 minutes post-administration
Reported as:
Median · Lesions
Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)
LesionsSonazoid™SonoVue®
Post-contrast minus Pre-contrast: Reader 10.0 (-1.0 to 1.0)0.0 (-1.0 to 0.0)
Post-contrast minus Pre-contrast: Reader 20.0 (-2.0 to 0.0)-1.0 (-2.0 to 0.0)
Post-contrast minus Pre-contrast: Reader 30.0 (-1.0 to 0.0)-1.0 (-2.0 to 0.0)
Post-contrast minus Reference: Reader 11.0 (0.0 to 2.0)1.0 (0.0 to 1.0)
Post-contrast minus Reference: Reader 20.0 (0.0 to 1.0)0.0 (0.0 to 0.0)
Post-contrast minus Reference: Reader 30.0 (0.0 to 1.0)0.0 (-1.0 to 1.0)
SecondaryNumber of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results

Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).

Time frame:
Pre-administration up to 15 minutes post-administration
Reported as:
Count of participants · Participants
Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results
ParticipantsSonazoid™SonoVue®
Reader 1: Pre-contrast — Definite (3 points)1011
Reader 1: Pre-contrast — Probable (2 points)113122
Reader 1: Pre-contrast — Not confident (1 point)4636
Reader 1: Pre-contrast — Unknown (0 points)00
Reader 1: Post Contrast — Definite (3 points)5754
Reader 1: Post Contrast — Probable (2 points)8688
Reader 1: Post Contrast — Not confident (1 point)1715
Reader 1: Post Contrast — Unknown (0 points)00
Reader 2: Pre-contrast — Definite (3 points)1512
Reader 2: Pre-contrast — Probable (2 points)8979
Reader 2: Pre-contrast — Not confident (1 point)6578
Reader 2: Pre-contrast — Unknown (0 points)00
Reader 2: Post-contrast — Definite (3 points)116103
Reader 2: Post-contrast — Probable (2 points)4351
Reader 2: Post-contrast — Not confident (1 point)44
Reader 2: Post-contrast — Unknown (0 points)00
Reader 3: Pre-contrast — Definite (3 points)3836
Reader 3: Pre-contrast — Probable (2 points)8990
Reader 3: Pre-contrast — Not confident (1 point)4242
Reader 3: Pre-contrast — Unknown (0 points)01
Reader 3: Post-contrast — Definite (3 points)130117
Reader 3: Post-contrast — Probable (2 points)3136
Reader 3: Post-contrast — Not confident (1 point)49
Reader 3: Post-contrast — Unknown (0 points)00
SecondaryPercentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth

The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.

Time frame:
Pre-administration up to 15 minutes post-administration
Reported as:
Number · percentage of participants
Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth
percentage of participantsSonazoid™SonoVue®
Reader 111.921.7
Reader 216.615.2
Reader 315.819.1

Adverse events

Collected over All Adverse Events (AEs) were collected from administration of investigational medicinal product (IMP) up to the 72 hours post injection regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sonazoid™0/218 (0%)0/218 (0%)0/218 (0%)
SonoVue®0/206 (0%)0/206 (0%)0/206 (0%)

Baseline characteristics

Analysis was performed on safety analysis set that included all enrolled participants who received either Sonazoid™ or SonoVue.

Age, Continuous
Age, Continuous(years)Sonazoid™SonoVue®Total
Mean54.5 ± 12.6152.2 ± 13.7753.4 ± 13.22
Sex: Female, Male
Sex: Female, Male(Participants)Sonazoid™SonoVue®Total
Female8181162
Male137125262
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sonazoid™SonoVue®Total
American Indian or Alaska Native000
Asian218206424
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

18 sites
  • Peking Union Medical College Hospital, East Campus: No.1 Shuaifuyuan Wangfujing
    Dongcheng, Beijing 100730, China
  • Chinese PLA General Hospital, No. 28 Fuxing Road
    Haidan, Beijing 100853, China
  • Peking Union Medical College Hospital, West Campus: No. 41 Damucang Hutong
    Xicheng, Beijing 100032, China
  • The First Affiliated Hospital, Sun-Yat sen University, No. 58 Zhongshan Second Road
    Guangzhou, Guangdong 510080, China
  • The Second Affiliated Hospital of Zhongshan University, No. 107 Yanjiang West Road
    Guangzhou, Guangdong 510120, China
  • Shanghai First Hospital, North Campus: No. 100 Haining Road
    Hongkou, Shanghai 200080, China
  • Shanghai First Hospital, South Campus: No.650 New Songjiang Road
    Songjiang, Shanghai 201620, China
  • Zhongshan Hospital Fudan University, No. 180 Fenglin Road
    Xuhui, Shanghai 200032, China
  • Shanghai Hua Shan Hospital, No. 12 Wulumuqi Middle Road
    Xuhui, Shanghai 200040, China
  • Shanghai Sixth Hospital, No. 600 Yishan Road
    Xuhui, Shanghai 200233, China
  • Shanghai Tenth People's Hospital, No. 301 Yanchang Middle Road
    Zhabei, Shanghai 200072, China
  • Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu
    Seoul, 110-744, Korea, Republic of
  • Seoul St Mary's Hospital, 222 Banpo-daero, Seocho-gu
    Seoul, 137-701, Korea, Republic of
  • National Taiwan University Hospital - Yunlin Branch, No. 579, Sec. 2 Yunlin Road
    Douliu, Yunlin County, Taiwan
  • National Taiwan University Hospital, No. 7 Chung-Shan South Road
    Taipei, 100, Taiwan
  • Mackay Memorial Hospital, No. 92, Sec. 2 Zhongshan N. Road
    Taipei, 10449, Taiwan
  • Cathay General Hospital, No. 280 Jen-Ai Road, Sec. 4
    Taipei, 10650, Taiwan
  • Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2
    Taipei, 112, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Apr 2015, 10 months.

Results were first posted in Aug 2018, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2017
First posted
Nov 7, 2017
StartActual
May 11, 2014
Primary completionActual
Apr 9, 2015
CompletionActual
Apr 9, 2015
Results first posted
Aug 27, 2018
Last update
Oct 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03335566
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
May 11, 2014
Primary completion
Apr 9, 2015
Completion
Apr 9, 2015
Results posted
Aug 27, 2018
Last update
Oct 31, 2018

Study contacts

Francois Tranquart, MD, PhD
study chair · GE Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonazoid

Start the discussion